Roche wins FDA's breakthrough therapy designation for autism drug

ZURICH, Jan 29 (Reuters) - Swiss drugmaker Roche said on Monday the U.S. Food and Drug Administration granted its breakthrough therapy designation for Balovaptan to treat autism spectrum disorder (ASD), potentially accelerating its development and approval.

by support@endlesssupplies.biz (Endless Supplies .Biz) via Endless Supplies .Biz - News